Breakthrough for 800 Million Patients? Kidney Disease Drug Shows Powerful New Benefits

Key Points:

• New research published in the New England Journal of Medicine shows that finerenone, previously used for diabetic kidney disease, can slow kidney function decline and reduce major health risks in chronic kidney disease (CKD) patients without diabetes.
• The international FIND-CKD trial involved 1,584 adults with CKD but no diabetes, demonstrating that finerenone significantly slowed the decline in estimated glomerular filtration rate (eGFR) and lowered risks of kidney complications, heart failure hospitalization, and cardiovascular death.
• Finerenone also reduced urinary protein levels by over 41% after six months, an important marker of kidney damage, with more than half of treated patients achieving a clinically meaningful reduction in proteinuria.
• These findings highlight finerenone as a safe and effective new treatment option for the large population of non-diabetic CKD patients, who currently have limited therapeutic alternatives to slow disease progression and reduce cardiovascular risks.